検索結果

da Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, J...

adquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 ...

Business Activities | About Senju | SENJU Pharmaceutical

Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph...

Management Policy | About Senju | SENJU Pharmaceutical

valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased sales. Action...

Overseas Activities | SENJU Pharmaceutical

nd pharmaceutical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we enter the era o...